Thus, an altered ANXA2-mediated fibrinolysis, in part due to enhanced induction of autoantibodies against ANXA2 triggered upon SARS-CoV-2 infection, might contribute to the complex pathophysiological mechanisms of COVID-associated coagulopathy. This evidence concerns the gene ANXA2 and blood coagulation disease.